Abstract 14P
Immunotherapy has changed clinical practise. Patient enrolment in immunotherapy phase I trials is still crucial. Therefore, new tests have been developed (GRIM score and LIPI score), challenging the classical ones designed for targeted therapy such as Royal Marsden Score (RMS). Although they include different variables, here we perform a comparison, aimed at identifying if there are differences in terms of their predictive power of survival.